Journal
MOVEMENT DISORDERS
Volume 24, Issue 7, Pages 949-964Publisher
WILEY
DOI: 10.1002/mds.22413
Keywords
multiple system atrophy; Parkinson; MRI; PET; SPECT
Categories
Funding
- NIH [1 R13 NS055459]
- Novartis Pharmaceuticals
- Chelsea Therapeutics
- American Academy of Neurology (AAN)
Ask authors/readers for more resources
In this article, we review the state of the art knowledge concerning structural and functional imaging in multiple system atrophy (MSA). The relative value of imaging modalities in the differential diagnosis of MSA from other parkinsonian syndromes is debated. It is concluded that, although neuroimaging biomarkers provide valuable supportive data along-side clinical assessments, it is not possible to use them as surrogate markers. (C) 2009 Movement Disorders Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available